A pioneering study led by the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore and the University of Cambridge (UK) has uncovered vital insights into the distinct effects of BRCA2 mutations on breast tissue cells, shedding light on early breast cancer development in people with BRCA2 mutations.
Tag: BRCA
Study Unlocks New Insight about Breast Cancer Risk
A new study led by a researcher at New York Institute of Technology provides insight that could change how scientists and clinicians understand genetic predisposition to breast cancer, a condition that affects one in eight U.S. women in her lifetime.
Identifying the Underlying Causes of Ovarian Cancer
Two new discoveries led by Cedars-Sinai Cancer investigators help improve the understanding of what drives the development of ovarian cancer and why some women’s tumors do not respond to therapy.
Breast Cancer Expert: “Awareness and Early Detection Save Lives”
One in eight women will be diagnosed with breast cancer in her lifetime. For those with BRCA1 and BRCA2 gene mutations, the chances are even higher. The National Breast Cancer Foundation estimates that 55 to 65% of women with the BRCA1 mutation, and 45%…
MD Anderson Research Highlights for August 25, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include clinical studies to investigate novel treatment strategies, a new understanding of cancer precursor lesions, identifying a calcium signaling receptor, characterizing nodal immune flair after immunotherapy, a community screening tool for BRCA testing and a new method for diagnosing Clostridioides difficile infections.
Black and White Women Have Same Mutations Linked to Breast Cancer Risk
The prevalence of genetic mutations associated with breast cancer in Black and white women is the same.
Mutations Commonly Linked to Breast Cancer Found to Pose No Increased Risk, Population Study Reveals
Several genetic mutations previously linked to breast cancer and included on commercial genetic tests, including direct-to-consumer tests, were found not to increase a woman’s risk of disease, according to a population study of more than 64,000 women published online today in the New England Journal of Medicine from several institutions, including Penn Medicine.
Penn’s Basser Center for BRCA Awards 2020 Basser Global Prize to Bella Kaufman from Israel’s Sheba Medical Center
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, is pleased to announce Bella Kaufman, MD, of the Sheba Medical Center in Tel-Hashomer, Israel, as the recipient of the eighth annual Basser Global Prize.
Ludwig San Diego Study Identifies Deadly Genetic Synergy in Cancer Cells and Shows it Might Be Exploited for Therapy
A Ludwig Cancer Research study has identified a new instance in which the simultaneous mutation of two nonessential genes—neither of which is on its own vital to cell survival—can cause cancer cell death.
A New Approach to Tailoring Cancer Therapy: Tapping Into Signaling Activities in Cancer Cells
The Weizmann Institute’s Dr. Ravid Straussman and colleagues developed a method that utilizes cellular signaling to determine the best treatment for a given tumor. The method can help tailor treatments and identify new drug-development targets. In fact, the team has already singled out a gene that serves as a target for treating BRCA-related breast cancers.